# A Study of CC-95266 in Participants With Relapsed and/or Refractory Multiple Myeloma

> **NCT04674813** · PHASE1 · COMPLETED · sponsor: **Juno Therapeutics, a Subsidiary of Celgene** · enrollment: 130 (actual)

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** CC-95266
- **DRUG:** Fludarabine
- **DRUG:** Cyclophosphamide
- **DRUG:** Bendamustine

## Key facts

- **NCT ID:** NCT04674813
- **Lead sponsor:** Juno Therapeutics, a Subsidiary of Celgene
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-02-24
- **Primary completion:** 2025-12-22
- **Final completion:** 2025-12-22
- **Target enrollment:** 130 (ACTUAL)
- **Last updated:** 2026-02-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04674813

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04674813, "A Study of CC-95266 in Participants With Relapsed and/or Refractory Multiple Myeloma". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT04674813. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*